No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer By Ogkologos - August 19, 2025 634 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTER 70s study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Young Mom With Metastatic Breast Cancer Travels To Mexico For Alternative... November 26, 2019 Saying YES: Inspiring a Diverse Generation of Cancer Scientists October 8, 2020 Should Surgery And Radiation Be The Standard Treatment For DCIS? The... May 14, 2019 Mom Who Fought Breast Cancer While Pregnant Describes The Benefits Of... January 20, 2020 Load more HOT NEWS 2023 ASCO Annual Meeting Research Round Up: Improving Symptom Monitoring and... The Taylor Family Foundation gives £2.1m to support head and neck... Consistent Efficacy Benefit with Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Patients... Sacituzumab Govitecan Demonstrates a Relatively High ORR with Rapid Responses in...
